Lynkuet Cuts Menopause Hot Flashes 73%, First NK1/NK3 Hormone-Free Drug
Hot flashes are not just an inconvenience. Waking drenched in the middle of the night, losing the thread of a thought as heat surges through your face in a meeting — for millions of women, menopause can feel less like a biological transition and more like a daily endurance test. On October 24, 2025, the FDA approved elinzanetant (Lynkuet, Bayer), the world’s first dual NK1 and NK3 neurokinin receptor antagonist for moderate to severe vasomotor symptoms due to menopause. In the OASIS-3 trial, it reduced hot flash frequency by more than 73% at 12 weeks, compared to 47% for placebo. No hormones involved.
Why Hot Flashes Can Be Stopped Without Hormones
The mechanism begins deep in the hypothalamus, the region of the brain that governs body temperature and hormonal signaling. Nestled there is a cluster of neurons called KNDy neurons, named for the three signaling molecules they release: kisspeptin, neurokinin B, and dynorphin.
When estrogen levels drop during menopause, KNDy neurons become hyperactivated. They release excess neurokinin B, which binds to NK3 receptors (proteins on hypothalamic neurons that receive heat-dissipation signals) and incorrectly triggers the body’s cooling response. That misfiring is the hot flash. Alongside this, substance P activates NK1 receptors involved in arousal and mood regulation, contributing to night sweats, disrupted sleep, and emotional volatility.
Lynkuet blocks both pathways simultaneously. It antagonizes both NK3 and NK1 receptors, effectively switching off the faulty thermostat alarm at its source. The predecessor in this drug class, fezolinetant (Veozah, approved by FDA in 2023), targeted only NK3. Lynkuet’s dual mechanism is what makes it a first-in-class therapy.
What the OASIS Trial Numbers Actually Mean
The FDA approval rests on data from three Phase III clinical trials conducted under the OASIS program.
OASIS 1 and OASIS 2 enrolled 796 menopausal women and ran for 12 weeks, comparing Lynkuet (60mg soft gel capsule, taken once daily at bedtime) against placebo. Co-primary endpoints measured change in the frequency and severity of moderate to severe hot flashes at weeks 4 and 12.
OASIS-3 followed 627 women for up to 52 weeks to evaluate long-term safety. In this trial, elinzanetant reduced moderate to severe hot flash frequency by more than 73% at week 12, versus 47% for placebo.
In practical terms: a woman experiencing 10 hot flashes a day would expect to drop to roughly 4 by week 4, and to around 2 by week 12. The mean reductions measured were 6 fewer per day at week 4, and 8 fewer at week 12.
Sleep improvement stands out as a secondary finding. Because NK1 receptor blockade also affects arousal regulation, sleep quality improved independently of hot flash reduction in some participants. Researchers estimated that approximately 54.3% of the observed sleep improvement was directly attributable to the drug’s mechanism, not simply a downstream effect of fewer nighttime hot flashes.
The Women Who Have Been Waiting for This
Hormone replacement therapy has long been the primary intervention for menopausal vasomotor symptoms, and for good reason. It works well and carries bone-protective benefits. But for women with a history of breast cancer, blood clots, or certain cardiovascular conditions, hormonal treatment is contraindicated. Until recently, the non-hormonal alternatives, including antidepressants, gabapentin, and clonidine, were medications designed for entirely different conditions, repurposed with partial and inconsistent results.
Lynkuet was studied specifically in a population that has historically had the fewest options. OASIS-4 enrolled 474 women with hormone receptor-positive breast cancer who were actively taking tamoxifen or aromatase inhibitors. These are women whose cancer treatment can itself intensify hot flashes, and who cannot turn to hormones for relief. The trial demonstrated meaningful efficacy and an acceptable safety profile in this group, marking the first time a non-hormonal therapy has been clinically validated in breast cancer patients on active hormonal therapy.
Women with blood clot risk, those who have experienced hormone-related side effects, and those who simply prefer to avoid hormone-based approaches now have a mechanistically distinct, FDA-approved option.
Side Effects and What to Know Before Starting
Common side effects reported in OASIS trials include headache, fatigue, dizziness, abdominal pain, rash, diarrhea, and muscle spasms. Hormone-related side effects such as blood clots, breast tenderness, or uterine bleeding are not associated with Lynkuet.
The most significant monitoring requirement is liver health. Liver function testing is recommended before starting Lynkuet and at the 3-month mark. Researchers suggest Lynkuet may carry a lower liver toxicity risk than fezolinetant, but head-to-head comparison data remain limited. Women with a history of seizure disorders should also consult their physician before starting.
In the US, the list price for a 30-day supply (60 capsules) is approximately $625. Through GoodRx or Bayer’s patient assistance program, eligible women may pay as little as $25 per month. Prior authorization is commonly required by insurance plans.
How to Think About the Choice Between Lynkuet and HRT
Lynkuet is not a replacement for hormone therapy. It is an addition to the landscape for women who cannot access, or choose not to use, hormonal treatment.
If there are no contraindications to HRT and symptoms are severe, estrogen-based therapy still offers the broadest benefit profile, including cardiovascular and bone density effects, alongside vasomotor symptom relief. For women where hormones are off the table, or where a non-hormonal approach is strongly preferred, Lynkuet represents the most mechanistically targeted option currently available, one designed specifically for the neurobiology of menopause rather than borrowed from another condition.
The fact that two neurokinin-targeted drugs now exist, fezolinetant and elinzanetant, suggests that this pathway is becoming a genuine therapeutic category. For decades, the message to women in menopause was largely to wait it out. The science has moved on from that.
Q. How is Lynkuet different from hormone replacement therapy (HRT)?
HRT replenishes estrogen to ease hot flashes, but carries risks for women with breast cancer or blood clot history. Lynkuet blocks the brain’s faulty thermostat signal without any estrogen, reaching the same goal through a completely different pathway.
Q. Can women on breast cancer treatment use Lynkuet?
The OASIS-4 trial specifically enrolled 474 women with hormone receptor-positive breast cancer on tamoxifen or aromatase inhibitors. Results showed meaningful efficacy and an acceptable safety profile, though liver function testing before and 3 months after starting is required.
Q. How quickly does Lynkuet work?
In clinical trials, women experienced 6 fewer hot flashes per day at week 4 and 8 fewer at week 12. Sleep improvements also appeared within the first 4 weeks, even in some women whose hot flash frequency had not yet fully declined.